Immupharma Share Discussion Threads

[ih_116147] 06/7/2020 11:35

DNL = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL

Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021

[zb27] 06/7/2020 11:32

Have you got your winning ticket.....

[zb27] 04/7/2020 15:30

I wonder what the 2 US healthcare funds know from their due diligence to have invested in IMM? I wonder what Dr Zimmer knows to have invested another £200k recently, and also Lanstead. Questions questions, I guess we all waiting very patiently.

[zb27] 04/7/2020 15:28

With so much news expected across the portfolio, I wonder what news will drop first.....Avion developments? Lupuzor FDA meeting? Ureka? Icanthera? Further commercial agreements? Lupuzor/Ureka help towards Covid 19? Or a big bang update, all at once?

[lord loads of lolly] 02/7/2020 15:03

You may be right - depends on whether the news is good or bad. You can never say any share is at its lowest unless it hits zero.

[halfbutt] 02/7/2020 14:19

This is due a spike very soon... it's at its lowest and will go mad as soon as news arrives.. that's how it historically behaves..

[wigwammer] 28/6/2020 18:38

Zb - your list yesterday was a good one and - as has been repeatedly expressed over the last day or two - the story is no longer just about lupuzor. After years of investment the other parts of the pipeline are reaching inflection and I suspect are significantly undervalued within the group. The most interesting thing about the last interview is TM was given carte blanche to bs about Covid if he chose to - and he declined. Perhaps he knows he doesn't need to. ATB

[nobbygnome] 28/6/2020 18:29

Twice recently I have held short positions and made money and in fact one time a long position too so it is constantly on my watch list. And I know an awful lot about Lupuzor having been associated with due dilligence on it when I worked in the industry and find it fascinating. The destruction of it's potential by the company is like a modern day tragedy....there is a half decent drug trying to get out but incompetent management have wrecked it.

[zb27] 28/6/2020 17:47

IMHO A lot lot more than the current market cap! Time will tell. You seem very fixated on Lupuzor? Currently no value has been attached to the Avion deal. The previous trial failed, the drug DID NOT FAIL. With all the data they have from the previous phase 3, they will succeed this time round in bringing it to the market. You also dont seem to acknowledge they now have many other drugs in development, A completely different company from a few years ago. Especially with no holding here! Why are you here? What is your agenda. Good constructive conversation is welcome. However you not going to sway us not to invest here spreading your rubbish.

[wigwammer] 28/6/2020 15:46

Absolutely. I lost the argument. Goodbye :)

[wigwammer] 28/6/2020 15:28

I believe therefore that tarny is entitled to his view that imm may be worth 50p, without you suggesting his view is from another planet. You don't have a position here. You haven't researched it properly. The people that count - the fda, avion, ii's - do not share your cynicism. So it's just the lack of conviction, lack of knowledge, and unprovoked attacks on other posters that lead people to think yer a pl0nker. Hope that helps :)

[wigwammer] 28/6/2020 15:04

"I don't dispute the price will go up ahead of the results" says nob. He hasn't researched the pipeline. As usual, he is just drawing attention to himself. Good luck holders :)

[nobbygnome] 28/6/2020 13:06

As i said earlier a lot of IIs got it wrong last time and they will again this time IMHO! Nothing has changed wrt Lupuzor and the inadequate dosing level.

[wigwammer] 28/6/2020 12:28

And unintentionally drawing attention to the inadequacies within yourself. Do some research. I'm sure the two US funds that just invested have :)

[nobbygnome] 28/6/2020 11:55

LOL. Actually I am drawing attention to the inadequacies of the company.......

[wigwammer] 28/6/2020 11:52

As stated, I am pleased you are sceptical. The two US funds that recently invested, Avion and the FDA (who previously backed the science into ph3) are not so sceptical. And they count. The pipeline appears to be maturing and broadening. Instead of succumbing to your instinct to come here and draw attention to yourself again - why not do a little research instead. ATB

[nobbygnome] 28/6/2020 11:08

So you are happy with the fact that there has been no announced progress with the FDA on the trial design? The deal was announced on the 28th November last year and here we are 7 months later with no approved trial protocol. Starting a trial this year is beginning to look unlikely and knowing that recruitment will be difficult for a trial with a drug which spectacularly failed first time round, actually I think 3 years until the results is looking a little ambitious.

[wigwammer] 28/6/2020 10:45

I take your scepticism as a positive, and forgive your past failings. Best :)

[nobbygnome] 28/6/2020 10:24

Thinking IMM with its dubious past and poor management is going to be worth £85 million+ in the short term is unrealistic IMHO. Come back in two-three years' time and if the Lupuzor trial is coming to its completion, then maybe. But in the short term, no chance IMHO......

And when are the FDA going to give approval for the trial? They said in February that Avion were meeting with the FDA in the first quarter to discuss the trial design. Here we are at the end of the second quarter and there has been no news. I would be a little concerned if I was a shareholder.....

[wigwammer] 28/6/2020 10:10

Zb27 - I agree. They have a fully funded ph3 with lupuzor, and a couple of other products they believe can be partnered and developed in short order and at low cost. Do I believe we can see 50p+ prior to read out with lupuzor alone? Yes. Do I believe that 50p+ target can be materially expedited as news flow relating to the other products is priced in? Yes. ATB

[zb27] 27/6/2020 14:43

Thanks for your insightful scientific advice.As I have said, Lupuzor isn't the only drug in development, the company has fundamentally changed, there is also significant work ongoing at Icanthera and Eureka which is in development.Lets see how everything progresses over the next several months, major news due on a variety of different programmes, which I believe will value IMM significantly more to the current market value. IMHO DYOR